Fact-checked by Grok 2 weeks ago

Neurosyphilis

Neurosyphilis refers to the infection of the central nervous system by Treponema pallidum, the spirochetal bacterium that causes syphilis, and can develop during any disease stage though it most frequently arises years after initial untreated infection. It encompasses several clinical syndromes—asymptomatic neurosyphilis, acute meningitis, meningovascular syphilis, tabes dorsalis involving spinal cord degeneration, and general paresis leading to progressive dementia and psychiatric disturbances—each driven by direct bacterial invasion, inflammatory responses, and vascular damage within neural tissues. Symptoms vary widely but commonly include severe headaches, sensory ataxia, lightning-like pains, pupillary light-near dissociation as in Argyll Robertson pupils, and cognitive decline, with progression halted only by timely antimicrobial intervention. Diagnosis integrates reactive cerebrospinal fluid VDRL testing, elevated protein or pleocytosis, and supportive serologic evidence, while definitive treatment requires prolonged intravenous penicillin G to achieve bactericidal concentrations in the central nervous system, as alternative regimens risk therapeutic failure. Amid a marked resurgence in syphilis cases—exceeding 130,000 annually in the United States by 2020—neurosyphilis incidence has risen correspondingly, disproportionately affecting HIV-positive individuals and the elderly, underscoring the need for vigilant screening in at-risk populations despite effective antibiotics rendering it largely preventable.

Definition and Overview

Definition

Neurosyphilis refers to of the (CNS), including the brain and spinal cord, by Treponema pallidum, the spirochete bacterium responsible for . This invasion can manifest as asymptomatic involvement, detectable through (CSF) abnormalities, or symptomatic disease affecting neurological function. Unlike the primary, secondary, or tertiary cutaneous and systemic stages of , neurosyphilis specifically denotes CNS penetration by the pathogen, which penetrates the blood-brain barrier and blood-CSF barrier during dissemination. The condition arises from untreated or inadequately treated , though it may develop early (within the first year of ) or late (years to decades after initial exposure). typically involves clinical evaluation combined with CSF analysis showing pleocytosis (elevated ), elevated protein, or reactive VDRL (, alongside serological evidence of . Historically rare in the antibiotic era, neurosyphilis persists in populations with limited healthcare access or high incidence, such as those with co-infection, where CNS invasion rates approach 40-60% in early cases.

Classification and Stages

Neurosyphilis is classified into early and late forms based on the interval from primary infection, with early neurosyphilis typically manifesting within the first two years and late neurosyphilis occurring more than two years after initial infection. Early forms include neurosyphilis, meningeal neurosyphilis, and meningovascular neurosyphilis, while late forms encompass parenchymatous types such as and general paresis (also known as dementia paralytica). This temporal distinction reflects differences in , with early invasion often involving acute inflammation of the or vasculature, and late stages characterized by chronic degenerative changes in neural . Asymptomatic neurosyphilis, the most common type, is defined by (CSF) abnormalities—such as pleocytosis, elevated protein, or reactive VDRL—without clinical neurologic symptoms, and it may occur in either early or late phases. , an early symptomatic form, presents with , stiff neck, and cranial nerve palsies due to basal meningitis, often within months to a year post-infection. Meningovascular neurosyphilis, also early (peaking 4-7 years after infection despite the general early classification), involves stroke-like events from or , leading to focal deficits such as . Late neurosyphilis primarily manifests as , affecting the dorsal columns and roots of the , resulting in , lightning pains, loss of , and Argyll Robertson pupils (accommodate but do not react to light), typically 15-20 years post-infection. General paresis involves progressive , personality changes, delusions, and tremors from widespread cortical atrophy and , emerging 10-30 years after untreated . Gummatous neurosyphilis, a rarer late variant, features space-occupying gumma lesions in the or , mimicking tumors with . These classifications guide via CSF analysis and inform treatment, as late stages respond less robustly to penicillin despite its efficacy across forms.

Epidemiology

Incidence and Prevalence

Neurosyphilis incidence parallels the resurgence of , occurring in a minority of cases but with rising absolute numbers due to increased primary and secondary diagnoses globally and in high-income countries. Worldwide, incidence grew by 60% from 1990 to 2019, with an estimated 8 million new adult infections in 2022 alone, elevating risks for involvement in untreated or inadequately treated individuals. In the United States, cases surpassed 130,000 in 2020, predominantly among men who have sex with men, with primary and secondary rates peaking before a 22% decline from 2023 to provisional 2024 data. Among reported cases, neurologic manifestations indicative of neurosyphilis affect approximately 1% of early-stage infections, with rates highest in secondary at 1.1%. From 2019 to 2022, the proportion of early cases with such manifestations rose from 0.6% to 1.0%, while late cases increased from 1.3% to 2.0%, reflecting diagnostic vigilance amid upticks. Historically, before widespread penicillin use, 30% of untreated progressed to neurosyphilis, including forms; modern remains lower due to early but persists at elevated levels in HIV-coinfected patients, where rates exceed those in HIV-negative individuals.00257-2/fulltext) Prevalence varies by population and diagnostic criteria, often underreported due to cases and inconsistent testing. In latent cohorts, neurosyphilis occurs in about 4% of patients per retrospective analyses. Among patients experiencing treatment failure, confirmed neurosyphilis reaches 15.8% in select studies, underscoring persistence in high-risk groups like those with . Local surveillance, such as 40 neurosyphilis, ocular, and otic cases in from January to October 2023 (67.5% HIV-negative), highlights urban hotspots amid broader trends. Overall, while exact global neurosyphilis incidence eludes precise tracking without universal screening, epidemics in vulnerable populations—elderly, HIV-positive, and men who have sex with men—drive proportional increases.

Risk Factors and Transmission Dynamics

Neurosyphilis develops as a complication of untreated infection caused by , with transmission of the spirochete occurring primarily through direct contact with infectious mucocutaneous lesions during the primary or secondary stages of . Sexual transmission predominates, involving oral, vaginal, or anal contact, while from infected mothers to fetuses during accounts for congenital cases that can manifest as neurosyphilis later in life. Bloodborne transmission via transfusions or needlestick injuries is rare in modern settings due to screening protocols. High-risk sexual behaviors significantly elevate the likelihood of acquisition and subsequent if untreated, including unprotected intercourse, multiple sexual partners, and practices common among men who have sex with men (MSM), who represent approximately 80% of primary and secondary cases in the United States. Co-infection with markedly increases the risk of , with persons living with exhibiting 1.3 times higher prevalence, elevated rates of neurologic invasion even in early , and greater serological treatment failure leading to persistent involvement. Among HIV-positive individuals, specific immunological and serological markers heighten neurosyphilis risk, such as counts below 350 cells/μL, (RPR) titers of 1:32 or higher, and unsuppressed viral loads exceeding 400 copies/mL, prompting recommendations for evaluation in these subgroups. In HIV-negative populations, older age (≥45–60 years) emerges as an independent , potentially linked to prolonged untreated duration and age-related immune decline. Demographic patterns indicate neurosyphilis occurs twice as frequently in males as females and 2–3 times more often in White individuals compared to Black individuals. Recreational drug use, particularly , correlates with increased transmission and neurosyphilis progression through facilitation of high-risk sexual networks, though direct causality remains associative rather than proven. Untreated or inadequately treated early universally poses the foundational risk for invasion, estimated to affect in 25–40% of cases during secondary , underscoring the imperative of prompt and penicillin-based to avert late complications.

Recent Trends and Resurgence

, neurosyphilis cases increased by 32% between 2020 and 2021, coinciding with a broader that saw primary and secondary rates rise from 2.1 per 100,000 in 2001 to 17.6 per 100,000 in 2021. This uptick reflects delayed diagnoses and reduced screening during the , exacerbating involvement in untreated infections. Nationally, cases surged 80% from 2018 to 2022, reaching over 207,000 reported infections, with neurosyphilis manifesting more frequently among men who have sex with men (MSM) and individuals with , though prevalence among HIV-positive persons stands at approximately 1.7%. Local surveillance data underscore the trend: in , 40 cases of neurosyphilis, ocular syphilis, or otic syphilis were reported from January to October 2023, compared to 16 cases in 2019, with 67.5% occurring in persons without HIV infection—up from 43.8% in 2019—and 54.5% in non-MSM individuals, indicating a broadening demographic risk profile. Median patient age was 46.5 years, with 72.5% male and 65% non-Hispanic Black. These shifts parallel rising heterosexual transmission and , which increased for the 12th consecutive year in 2024 with nearly 4,000 U.S. newborn cases. In , syphilis notification rates reached 9.9 per 100,000 in 2023 across 29 EU/EEA countries, a 13% rise from 2022 and double the 2014 figure, driving neurosyphilis incidence estimates of 0.16 to 2.1 per 100,000 adults annually. Globally, incidence climbed 60% from 1990 to 2019, with neurosyphilis resurgence linked to early invasion in up to 40% of untreated cases, particularly amid co-infections like . Enhanced diagnostics, including analysis, have improved detection, but untreated progression remains a key driver.

Etiology and Pathophysiology

Causative Organism

subspecies pallidum is the causative agent of neurosyphilis, a late manifestation of the . This spirochetal bacterium is a thin, motile, helical measuring 6–20 μm in length and 0.1–0.2 μm in diameter, with 6–14 periplasmic flagella that confer its characteristic corkscrew motility essential for tissue invasion. As an , T. pallidum subsp. pallidum cannot be routinely cultured on artificial media due to its fastidious nutritional requirements and sensitivity to environmental conditions, relying instead on mammalian hosts for replication, with a division time of approximately 30–33 hours. The bacterium's invasiveness enables early hematogenous dissemination from cutaneous or mucosal entry sites to the (CNS), often detectable within weeks of primary infection, independent of status. CNS invasion by T. pallidum subsp. pallidum triggers an inflammatory response involving treponemal antigens and host immune activation, contributing to the diverse neuropathological outcomes of neurosyphilis, though the organism's "stealth" adaptations—such as limited surface protein expression and immune evasion—allow persistent infection despite humoral responses. Genetic analyses confirm its distinction from non-pathogenic treponemes, with a small (~1.14 ) encoding genes for , , and antigenic variation that facilitate neuroinvasion.

Invasion of the Central Nervous System

Treponema pallidum subspecies pallidum, the causative agent of , gains initial access to the host via microabrasions in or mucous membranes during sexual , followed by rapid hematogenous dissemination that enables early of the (CNS). This dissemination occurs within weeks of primary infection, with spirochetes detectable in (CSF) as early as 10-90 days post-inoculation via rabbit infectivity testing or assays. CNS entry is not confined to late-stage disease but manifests in up to 40-70% of early cases, often asymptomatically, as evidenced by CSF pleocytosis or positive VDRL tests in untreated secondary patients. The spirochete breaches the blood-brain barrier (BBB) through targeted molecular interactions that disrupt endothelial integrity without relying on toxin production. Key virulence factors include Tp0751, a T. pallidum lipoprotein that binds to host laminin and alters tight junction proteins (e.g., occludin and claudin-5) in brain microvascular endothelial cells, thereby increasing paracellular permeability. Complementary mechanisms involve TpF1-mediated inhibition of microglial migration and induction of endothelial apoptosis, alongside Tp0965-promoted interleukin-6 (IL-6) secretion, which collectively facilitate transcellular and paracellular traversal. Host responses exacerbate this process; for instance, ADAMTS5, a matrix metalloproteinase upregulated during infection, degrades extracellular matrix components in the BBB, enhancing spirochete influx. Despite widespread early CNS invasion, progression to symptomatic neurosyphilis is infrequent, occurring in approximately 10-25% of untreated cases, due to partial immune containment or spontaneous clearance of organisms from CSF. Factors influencing persistence include genetic (e.g., variations in genes) and spirochete strain differences in adhesin expression, though empirical data remain limited by challenges in culturing T. pallidum. Persistent invasion correlates with chronic low-level , as T. pallidum evades via surface antigenic variation and low opsonic potential, allowing latent residence in neural tissues.

Progression and Tissue Damage

Treponema pallidum subsp. pallidum invades the central nervous system (CNS) shortly after primary infection, typically via hematogenous dissemination or direct extension from infected tissues into cerebrospinal fluid (CSF), breaching the blood-brain barrier through mechanisms including cytokine-induced endothelial disruption and bacterial motility. This early invasion often remains asymptomatic, with spirochetes persisting in a low-density, immunologically privileged state within CSF, meninges, and parenchyma, evading full clearance by host defenses despite resolution of systemic infection. Progression to symptomatic neurosyphilis occurs in approximately 10-25% of untreated cases over years to decades, driven by cumulative bacterial replication and host immune responses that fail to eradicate the organism. Chronic constitutes the primary driver of , initiated by spirochete antigens triggering a compartmentalized CSF involving T-cell infiltration, release (e.g., IL-6, TNF-α), and microglial activation, which paradoxically sustains rather than resolves infection. In meningovascular forms, endarteritis obliterans affects the , causing intimal , , and ischemic infarction of cerebral or spinal , with infarcts often multifocal and leading to stroke-like events within 4-10 years of infection. Parenchymatous progression involves direct spirochetal invasion of neural , resulting in , astrocytic proliferation, and neuronal ; in general , this manifests as cortical , demyelination, and accumulation of tau-like proteins mimicking neurodegenerative pathologies. Tabes dorsalis exemplifies late degenerative damage, where repeated inflammatory episodes target dorsal root ganglia and posterior columns, causing demyelination, axonal degeneration, and fibrosis without active spirochetes in all cases, leading to proprioceptive loss and over 15-30 years. Gummatous neurosyphilis, less common, involves granulomatous masses from hypersensitivity reactions, eroding dura and compressing neural structures to produce focal necrosis and seizures. Overall, damage arises not solely from bacterial —which is minimal due to T. pallidum's non-invasive metabolism—but from host-mediated vascular occlusion, , and amplifying neuronal vulnerability.

Clinical Manifestations

Asymptomatic Neurosyphilis

Asymptomatic neurosyphilis represents (CNS) by Treponema pallidum without clinical neurological manifestations, identified primarily through (CSF) abnormalities such as a reactive Venereal Disease Research Laboratory (VDRL) test, exceeding 5 per microliter, protein concentration above 45 mg/dL, or positive treponemal-specific tests in CSF. The CSF-VDRL assay demonstrates high specificity (nearly 100%) for neurosyphilis diagnosis, though its sensitivity is lower at approximately 30-70% in asymptomatic cases, necessitating complementary findings like elevated cell counts or protein to confirm invasion. This form typically emerges in the early phase of (within 1-2 years of primary ) but can persist or develop in latent stages. Prevalence varies by population and syphilis stage, with neurosyphilis constituting the most frequent neurosyphilis subtype overall. Among patients with latent , rates approximate 13.5%, while in serofast individuals (persistent low-titer nontreponemal antibodies post-treatment), pooled estimates reach 13% in HIV-uninfected cases and up to 34.6% in specific cohorts like untreated serofast in , where factors such as age over 50, non-Han , and titers ≥1:4 correlate with elevated . In HIV-coinfected patients, incidence is markedly higher, with 22% of early-stage cases showing CSF involvement upon , attributed to impaired immune clearance of spirochetes. Lower estimates, such as 4% in some tertiary care latent cohorts, highlight diagnostic underascertainment due to selective CSF testing. Although lacking overt symptoms like , cranial nerve deficits, or , untreated neurosyphilis risks progression to symptomatic variants, including meningovascular or , with historical data indicating 20-30% advancement over years in pre-antibiotic eras. In modern contexts with penicillin availability, however, the prognostic significance of isolated CSF findings remains debated, as longitudinal studies show limited evidence that routine detection alters long-term outcomes beyond ensuring adequate therapy. Guidelines recommend CSF evaluation in high-risk scenarios, such as comorbidity, neurological symptoms, or treatment failure, to guide intravenous penicillin regimens rather than oral alternatives.

Meningeal and Meningovascular Forms

Meningeal neurosyphilis, an early manifestation of invasion by , typically occurs within the first year of infection, though cases may present up to two years post-primary . It involves acute or subacute of the leptomeninges, leading to symptoms resembling bacterial , including severe , , , , , and fever. Cranial nerve involvement is common, manifesting as deficits such as , , facial palsy, or vertigo, while seizures or altered mental status may occur in severe cases. analysis often reveals pleocytosis with lymphocytic predominance, elevated protein, and normal glucose, confirming the inflammatory process. Meningovascular neurosyphilis combines meningeal inflammation with obliterative endarteritis of cerebral or spinal vessels, typically emerging 4 to 7 years after initial infection but occasionally earlier. This form predisposes to ischemic strokes, transient ischemic attacks, or rarely, intracranial aneurysms due to vascular narrowing and thrombosis, resulting in focal neurological deficits such as hemiparesis, aphasia, sensory loss, or gait instability. Patients may exhibit overlapping meningeal signs alongside cerebrovascular symptoms, including vertigo, confusion, or seizures from infarcts in watershed areas. Imaging, such as MRI, frequently shows multifocal infarcts or leptomeningeal enhancement, underscoring the vasculitic pathology. Untreated, it carries a high risk of permanent disability from recurrent vascular events.

Parenchymatous Forms

Parenchymatous neurosyphilis encompasses late-stage manifestations characterized by direct invasion and degeneration of the parenchyma, primarily involving and . These forms typically emerge 15 to 30 years after primary infection in untreated cases, reflecting chronic spirochetal persistence and resultant tissue destruction. General primarily affects the and subcortical structures, leading to progressive neuropsychiatric deterioration. Early symptoms include , impairment, alterations, and mood lability, progressing to , delusions of grandeur, hallucinations, seizures, and motor disturbances such as tremors and . may reveal , pupillary abnormalities, and pyramidal tract signs, with histopathological evidence of neuronal loss, , and spirochetal presence in brain tissue. The condition, historically termed "general paralysis of the insane," was a leading cause of institutionalization before antibiotics, with mortality approaching 100% within 2-5 years if untreated. Tabes dorsalis targets the dorsal columns and roots of the spinal cord, causing demyelination and atrophy that manifest as sensory ataxia, lightning-like lancinating pains in the limbs or trunk, and visceral crises such as gastric or rectal pain. Key clinical features include loss of proprioception and vibratory sense, absent deep tendon reflexes (especially ankle jerks), positive Romberg sign, and Argyll Robertson pupils exhibiting light-near dissociation. Additional complications encompass Charcot joints (neuropathic arthropathy), urinary incontinence, and optic atrophy, with symptoms often fluctuating but inexorably worsening without intervention. In contemporary settings, tabes dorsalis remains rare due to penicillin therapy but has been documented in cases of inadequate treatment or HIV coinfection. Distinguishing these forms clinically relies on predominant involvement—cerebral in general paresis versus spinal sensory in —though overlap can occur, with up to 20% of cases showing combined features. Diagnosis confirmation requires analysis demonstrating pleocytosis, elevated protein, and reactive VDRL, alongside serological positivity.

Ocular and Otosyphilis

Ocular syphilis encompasses syphilitic involvement of various eye structures, with posterior and panuveitis representing the most frequent manifestations. Symptoms often include eye pain, redness, , , and potentially severe vision loss or blindness if untreated. These presentations can arise at any stage of syphilis, though they are more common in secondary or tertiary disease, and may occur unilaterally or bilaterally. A classic sign is the , characterized by miotic, irregular pupils that accommodate to near stimuli but fail to constrict to light, resulting from damage to the pretectal nuclei by . Other ocular findings include , , , and retinal vasculitis. Otosyphilis, a neurosyphilitic manifestation affecting the and , typically presents with , , vertigo, and disequilibrium. These symptoms stem from treponemal invasion of the , vestibular apparatus, or auditory-vestibular pathways, potentially leading to irreversible damage without prompt intervention. Otosyphilis can mimic other otologic disorders and may coexist with ocular involvement, complicating . Incidence data indicate ocular syphilis affects approximately 1-3.5% of reported cases, while otosyphilis is rarer at about 0.4%, with rising trends amid broader syphilis resurgence. Both forms underscore the need for heightened clinical suspicion in at-risk populations, as early detection via serologic testing and analysis can preserve function.

Diagnosis

Clinical Assessment

Clinical assessment of neurosyphilis relies on eliciting a history of untreated or inadequately treated alongside neurological symptoms, followed by a targeted physical and to identify suggestive signs. Patients may report insidious onset of symptoms including chronic headaches, such as memory loss or , sensory disturbances like pains or paresthesias, instability, or psychiatric manifestations in late forms. Risk factors include coinfection, which lowers the threshold for suspicion due to accelerated progression and atypical presentations, and late latent duration exceeding one year. A thorough sexual and exposure history is essential, as primary or secondary seropositivity without prior heightens concern. Neurological examination should encompass evaluation of all , mental status, motor function, sensory modalities, reflexes, coordination, and . Classic findings include Argyll Robertson pupils, characterized by accommodation to near stimuli but absent light response, optic atrophy, in approximately 50% of cases, and impaired or vibration sense in nearly half. In , a parenchymatous form, patients exhibit positive Romberg sign, ataxic , and Argyll Robertson pupils due to dorsal column degeneration. Meningovascular syphilis may present with acute stroke-like deficits, meningismus, or focal cranial nerve palsies such as or vision changes. General paresis involves tremulousness, , hyperreflexia, and extensor plantar responses alongside . Ocular and auditory assessments are critical, with slit-lamp examination for or fundoscopy for in ocular syphilis, and for sensorineural hearing loss in otosyphilis. In HIV-positive individuals, even subtle or absent symptoms warrant scrutiny, as up to 40% may develop asymptomatic neurosyphilis detectable only via cerebrospinal fluid analysis. Clinical findings alone cannot confirm , as they overlap with other neuropathologies like or mimics, necessitating serological correlation and if neurosyphilis is suspected. Early detection through vigilant prevents irreversible damage, though late presentations often yield persistent deficits despite .

Serological and CSF Testing

Serological diagnosis of , a prerequisite for evaluating neurosyphilis, employs nontreponemal tests such as the (RPR) or Venereal Disease Research Laboratory (VDRL) for initial screening due to their ability to quantify antibody titers and monitor disease activity, followed by confirmatory treponemal tests including the (TP-PA), fluorescent treponemal antibody absorption (FTA-ABS), or enzyme immunoassays (EIA). Reactive serum serology indicates treponemal infection but lacks specificity for (CNS) involvement, necessitating CSF examination in symptomatic cases to distinguish neurosyphilis from systemic . High nontreponemal titers (e.g., RPR ≥1:32) may correlate with active disease but do not reliably predict neurosyphilis without CSF data. Cerebrospinal fluid (CSF) analysis via is indicated for patients with reactive serum and neurological symptoms such as cranial nerve deficits, , , or , though it may be deferred in isolated ocular or auditory with confirmed end-organ findings absent other CNS signs. The CSF-VDRL remains the reference standard for direct detection of antitreponemal antibodies produced intrathecally, demonstrating high specificity (78.2%–99%) that renders a positive result (undiluted and uncontaminated by blood) diagnostic for neurosyphilis, albeit with limited (66.7%–87.5%) that fails to exclude the condition when negative. Supportive CSF parameters include (>5 /mm³ in non-HIV patients or >20/mm³ in HIV-coinfected individuals), elevated protein (>45–50 mg/dL), and occasionally reduced glucose, which collectively bolster diagnostic probability when VDRL is nonreactive. Treponemal-specific CSF tests, such as CSF-FTA-ABS or CSF-TP-PA, provide greater sensitivity (75.6%–100%) for detection but reduced specificity owing to passive of antibodies across a compromised blood-brain barrier, limiting their utility to scenarios where CSF-VDRL is negative yet clinical suspicion persists. CSF (RPR), while sometimes employed, exhibits comparable or inferior performance to VDRL and is not routinely recommended. Overall, integrates reactive serology, compatible clinical features, and CSF abnormalities, as no isolated test suffices due to variable test performance and potential for false negatives. Emerging markers like CSF show promise for enhanced detection, particularly in HIV-associated cases, but lack standardized validation.

Diagnostic Challenges and Differential Diagnosis

Diagnosing neurosyphilis presents significant challenges due to the absence of a definitive gold standard test, relying instead on a combination of clinical suspicion, serological evidence of syphilis, and cerebrospinal fluid (CSF) abnormalities, which often yield inconclusive results. The clinical manifestations are highly variable and can occur at any stage of syphilis, mimicking numerous neurological, psychiatric, and infectious conditions, particularly in late stages where symptoms may develop decades after initial infection. Invasive procedures like lumbar puncture are required for CSF analysis, but patient refusal or contraindications, such as coagulopathy, further complicate evaluation. In immunocompromised individuals, such as those with HIV, atypical presentations and serological discrepancies increase diagnostic uncertainty. Serological testing for neurosyphilis lacks optimal ; while treponemal tests (e.g., TP-PA or FTA-ABS) confirm prior exposure with near-100% sensitivity, they do not distinguish active (CNS) involvement. CSF-VDRL remains the most specific test for active neurosyphilis, with specificity approaching 100%, but its sensitivity is low at 27-58%, leading to frequent false negatives in early or cases. CSF treponemal tests offer higher sensitivity (up to 100% for FTA-ABS) but reduced specificity due to passive from , necessitating interpretation alongside CSF pleocytosis ( count >5 cells/μL), elevated protein (>45 mg/dL), or clinical findings. Molecular tests like for in CSF show promise but limited availability and variable sensitivity (50-70%), restricting their routine use. Differential diagnosis requires distinguishing neurosyphilis from other entities based on specific clinical forms: Empirical treatment is sometimes initiated in high-risk cases with reactive serum tests and neurological symptoms despite negative CSF-VDRL, underscoring the need for heightened clinician awareness amid rising incidence.

Treatment

Primary Therapeutic Approaches

The primary therapeutic approach for neurosyphilis involves high-dose intravenous administration of aqueous crystalline penicillin G, which remains the only regimen with documented efficacy in eradicating from the due to its ability to achieve bactericidal concentrations in (CSF). The standard regimen, as recommended by the Centers for Disease Control and Prevention (CDC), consists of 18–24 million units per day, administered as 3–4 million units intravenously every 4 hours or via continuous infusion, for a minimum of 10–14 days. This parenteral route is essential because intramuscular benzathine penicillin G, effective for early stages, fails to penetrate the CSF adequately and is not recommended as monotherapy for neurosyphilis. For patients with penicillin allergy, penicillin desensitization followed by the standard regimen is preferred, as alternative agents like doxycycline (oral, 100 mg twice daily for 28 days) or ceftriaxone (2 g intramuscularly or intravenously daily for 10–14 days) lack robust clinical trial data supporting their efficacy and may not reliably clear central nervous system infection. Following completion of intravenous therapy, some guidelines suggest adjunctive weekly intramuscular benzathine penicillin G (2.4 million units) for 1–3 weeks to address potential coexisting latent syphilis, though this does not substitute for the initial neurosyphilis-specific treatment. Treatment decisions should incorporate CSF examination results, with normalization of CSF parameters (e.g., pleocytosis and VDRL reactivity) as a goal for assessing response, though serological cure may not always correlate with clinical improvement in advanced cases.

Considerations for HIV-Coinfected Patients

Patients coinfected with exhibit a higher incidence of neurosyphilis compared to those without , with studies reporting rates up to 1-2% among HIV-positive individuals with , particularly in those with low counts or high viral loads. This elevated risk stems from -induced immune dysregulation, which facilitates Treponema pallidum invasion of the , often presenting asymptomatically or with atypical features such as meningovascular involvement. Recommended treatment for neurosyphilis in -coinfected patients mirrors that for immunocompetent individuals: aqueous crystalline penicillin G at 18-24 million units per day, administered as 3-4 million units intravenously every 4 hours or via continuous infusion, for 10-14 days. This regimen achieves treponemicidal levels in (CSF), with no evidence supporting altered dosing or duration specifically for HIV status; alternatives like (1-2 g IV daily for 10-14 days) may be considered in penicillin-allergic cases based on limited observational data showing comparable efficacy. Desensitization to penicillin is preferred over non-penicillin options due to superior outcomes in CSF sterilization. Key considerations include pre-treatment (LP) for all HIV-positive patients with late latent , neurological symptoms, or evidence of ocular/otic involvement, as CSF abnormalities occur in up to 40% of such cases even without overt symptoms. Post-treatment, closer monitoring is advised due to reported serologic failure rates of 5-10% and potential neurological relapse, involving repeat CSF VDRL testing at 6-12 months and clinical follow-up every 3-6 months. Initiation or optimization of antiretroviral therapy (ART) concurrently with treatment enhances immunological recovery and reduces serologic non-response risk, though timing should avoid (IRIS) exacerbation of syphilitic inflammation. Jarisch-Herxheimer reactions occur in approximately 20-30% of treated neurosyphilis cases in patients, potentially more severe due to underlying , necessitating hospitalization for observation during initial dosing. Multidisciplinary management involving infectious disease specialists is essential, given comorbidities like opportunistic infections that may confound or response .

Monitoring and Follow-Up

Following penicillin therapy for neurosyphilis, patients must be monitored for the Jarisch-Herxheimer reaction, which manifests as fever, , , myalgias, and worsening neurological symptoms within 2-24 hours in approximately 20-50% of cases due to rapid treponemal lysis and cytokine release. Hospitalization or close observation is advised during initial treatment doses, particularly for those with meningovascular involvement, to manage symptoms supportively with antipyretics and hydration. Clinical follow-up involves serial neurological examinations to assess for symptom resolution or progression, typically at 3, 6, and 12 months post-, with more frequent evaluations if baseline deficits persist. Quantitative serum nontreponemal tests (e.g., RPR or VDRL) are performed at 3, 6, 9, 12, 18, and 24 months, aiming for a fourfold decline within 6-12 months as an indicator of response; failure to achieve at least a 75% decline by 12 months or a fourfold rise suggests possible reinfection or inadequate . Serum normalization correlates with (CSF) improvement in most cases. CSF examination via is repeated at 6 months post-therapy, then every 6 months until normalization of count (<5 cells/μL), protein level (<45 mg/dL), and VDRL titer (nonreactive or fourfold decline); this typically requires 1-2 years but may persist longer in advanced disease. Routine repeat CSF testing may be omitted in patients without HIV who demonstrate clinical improvement and serologic response, per CDC guidance, though persistent abnormalities after 2 years warrant retreatment consideration. In HIV-coinfected patients, monitoring is intensified due to slower serologic responses and higher relapse rates (up to 10-20%), with CSF evaluations every 3-6 months initially and annual serology thereafter, regardless of antiretroviral therapy status; retreatment is indicated for persistent CSF pleocytosis or clinical deterioration. Overall treatment success is evidenced by sustained clinical stability, serologic decline, and CSF normalization, while failure criteria include rising titers, unresolved CSF inflammation, or neurological worsening, prompting alternative regimens like extended penicillin courses.

Prognosis and Complications

Potential Outcomes

Untreated neurosyphilis invariably progresses to debilitating neurological complications, including tabes dorsalis with sensory ataxia, lancinating pains, and loss of proprioception; general paresis featuring progressive dementia, personality changes, and psychosis; and meningovascular syphilis causing strokes and cranial nerve palsies, often culminating in permanent disability or death within years to decades post-infection. Prompt antibiotic treatment with high-dose intravenous penicillin eradicates Treponema pallidum from the central nervous system in most cases, halting disease progression and normalizing cerebrospinal fluid parameters such as white blood cell count and VDRL titer within 6 to 12 months for responsive patients. In early forms like asymptomatic or meningeal neurosyphilis, clinical symptoms frequently resolve completely, restoring patients to baseline health. However, late-stage manifestations yield partial improvement at best, with serological cure rates around 82-88% but clinical resolution as low as 18-44%, and persistent neurological sequelae in approximately 42% of cases, including brain atrophy, infarcts, and demyelination evident on neuroimaging. Outcomes hinge critically on diagnostic timing and pre-treatment damage extent; delayed intervention correlates inversely with recovery, while HIV coinfection elevates treatment failure risk and CSF abnormality persistence. Despite bactericidal efficacy, penicillin does not regenerate destroyed neural tissue, rendering advanced deficits like or irreversible in many instances.

Irreversible Sequelae

Advanced neurosyphilis, particularly its parenchymatous forms, often results in irreversible central nervous system damage despite timely antibiotic intervention, with outcomes depending on disease stage at diagnosis. In general paresis, chronic inflammation leads to neuronal loss and gliosis in the cerebral cortex, manifesting as permanent cognitive deficits, including dementia, memory impairment, and executive dysfunction; treatment halts progression but rarely restores pre-existing brain tissue degeneration. Similarly, tabes dorsalis causes demyelination and atrophy of the dorsal root ganglia and posterior columns, yielding enduring sensory ataxia, proprioceptive loss, and lancinating pains that persist post-penicillin therapy due to non-regenerative axonal damage. Pupillary abnormalities, such as —miotic, irregular pupils unreactive to light but accommodating to near vision—reflect midbrain lesions that do not reverse, serving as a persistent marker of prior syphilitic involvement even after bacterial clearance. Motor sequelae, including spastic paraparesis or (Charcot joints), may also endure, with joint destruction and instability requiring ongoing orthopedic management as neural protective mechanisms fail permanently. Delayed diagnosis exacerbates these outcomes, with studies indicating that severe manifestations like irreversible psychiatric decompensation or blindness occur in up to 20-30% of late-treated cases. Long-term follow-up reveals that while serological response to (typically 18-24 million units daily for 10-14 days intravenously) prevents further deterioration, residual deficits correlate with pretreatment cerebrospinal fluid pleocytosis and protein elevation, underscoring the need for early intervention to minimize non-reversible neuronal injury. In HIV-coinfected patients, irreversible sequelae rates may rise due to accelerated disease progression, with persistent neurocognitive disorders reported in cohort studies despite combined antiretroviral and anti-syphilitic regimens.

Treatment-Related Reactions

The Jarisch-Herxheimer reaction (JHR) represents the primary treatment-related reaction observed following penicillin initiation for neurosyphilis, characterized by an acute systemic inflammatory response triggered by the rapid lysis of Treponema pallidum spirochetes and subsequent release of lipoproteins, which provoke cytokine production including tumor necrosis factor-alpha and interleukin-6. This reaction typically manifests within 2 to 24 hours of the first dose of aqueous crystalline penicillin G, the standard regimen involving 18-24 million units daily administered intravenously in divided doses or continuous infusion for 10-14 days. Symptoms of JHR in neurosyphilis patients include fever, chills, headache, myalgias, arthralgias, and tachycardia, with potential exacerbation of preexisting neurological deficits such as meningitic signs or focal weaknesses due to heightened cerebrospinal fluid inflammation; rigors and hypotension occur less frequently but can necessitate hospitalization in severe cases. In contrast to early syphilis, where JHR incidence ranges from 8% to 56%, its occurrence in late-stage neurosyphilis appears lower, estimated at around 10-20% based on cohort studies of HIV-negative patients, though data remain limited by small sample sizes and retrospective designs. Management focuses on supportive care, with antipyretics such as acetaminophen or nonsteroidal anti-inflammatory drugs recommended for mild symptoms to alleviate fever and discomfort, typically resolving within 12-24 hours without interrupting antibiotic therapy. For severe JHR involving significant neurological deterioration or hemodynamic instability, adjunctive corticosteroids like prednisone (1 mg/kg orally for 1-3 days) may attenuate the response by suppressing cytokine release, though evidence derives primarily from early syphilis trials and lacks randomized controlled data specific to neurosyphilis. Prophylactic steroids are not routinely advised due to risks of masking persistent infection or delaying diagnosis of treatment failure, but patient counseling on JHR risk is essential per CDC guidelines to mitigate anxiety and ensure prompt reporting of symptoms. Distinguishing JHR from penicillin allergy or disease progression is critical, as the former self-limits while the latter may require regimen adjustment; CSF monitoring post-treatment can reveal transient pleocytosis increases attributable to JHR rather than inadequate treponemicidal activity. Rare reports document prolonged or recurrent JHR in , potentially linked to high spirochetal burden, underscoring the need for inpatient initiation of therapy in symptomatic cases.

Prevention Strategies

Behavioral and Primary Prevention

Behavioral prevention of syphilis, which is essential to avert progression to neurosyphilis, centers on reducing sexual transmission risk through practices such as consistent condom use during vaginal, anal, or oral sex, as condoms barrier infectious chancres and other lesions when covering affected areas. Limiting sexual partners or engaging in mutual monogamy with a partner confirmed free of infection via testing further mitigates exposure, particularly in high-prevalence populations like (MSM). Abstinence from sexual activity eliminates transmission risk entirely. Primary prevention strategies emphasize education and access to barrier methods, with evidence from controlled studies indicating that promoting correct and consistent condom use can reduce syphilis incidence by up to 50% in targeted interventions among at-risk groups. For MSM and other high-risk individuals, emerging post-exposure prophylaxis with doxycycline (200 mg taken within 72 hours after condomless sex) has demonstrated reductions in syphilis acquisition by 73% in randomized trials, though it is not yet universally recommended pending larger-scale validation and regulatory approval. Public health campaigns focusing on awareness of syphilis symptoms, such as painless genital ulcers in primary stage, encourage early avoidance of potentially infectious contacts. Avoiding substance use that impairs judgment, such as alcohol or illicit drugs during sexual encounters, supports adherence to these behaviors by preserving decision-making capacity. Unlike viral STIs, lacks a vaccine, underscoring reliance on these non-pharmacologic measures as the cornerstone of primary prevention.

Screening Protocols

Lumbar puncture for cerebrospinal fluid (CSF) examination remains the cornerstone of screening for neurosyphilis in patients with , as no reliable noninvasive test exists to definitively rule out central nervous system involvement. The Centers for Disease Control and Prevention (CDC) recommends performing lumbar puncture in all individuals with exhibiting neurologic symptoms (such as headache, cognitive impairment, or meningismus), ocular manifestations (e.g., uveitis or retinitis), or otic symptoms (e.g., hearing loss or vertigo), regardless of disease stage. For these cases, CSF analysis includes VDRL testing, cell count, protein level, and glucose; a reactive CSF-VDRL (specific but not sensitive) or CSF pleocytosis (white blood cell count >5 cells/μL in HIV-uninfected or >20 cells/μL in HIV-infected patients) with a reactive serum treponemal test supports the . In asymptomatic patients, routine lumbar puncture is not universally recommended due to limited evidence of benefit and procedural risks, but CDC guidelines advise it for those with late latent , of unknown duration, or serologic treatment failure, as these stages carry higher risk of asymptomatic neurosyphilis. coinfection heightens the indication threshold; lumbar puncture is suggested for all HIV-positive patients with late latent or unknown duration, and consideration is given for early if CD4 counts are low (<350 cells/μL) or rapid plasma reagin (RPR) titers exceed 1:32, reflecting increased invasion potential of Treponema pallidum into the CSF. Some experts advocate broader criteria, such as routine CSF testing in patients with any stage and high titers (≥1:8), to detect subclinical involvement, though prospective data on outcomes remain sparse. Prior to lumbar puncture, all syphilis patients should undergo testing, as coinfection prevalence exceeds 10-20% in high-risk groups like men who have sex with men (MSM), and it correlates with atypical presentations and higher neurosyphilis rates. Initial syphilis screening via (nontreponemal tests like RPR followed by treponemal confirmation) in at-risk populations—such as sexually active MSM (annually or every 3-6 months if high-risk), pregnant individuals, and those with multiple partners—enables early detection to prevent progression to neurosyphilis, with CDC emphasizing prompt evaluation for neurologic in these cohorts. False-negative CSF-VDRL occurs in up to 30-70% of neurosyphilis cases, underscoring the need for clinical correlation and repeat testing if suspicion persists.

Public Health Measures

Public health measures targeting neurosyphilis focus on syphilis surveillance, early detection, and intervention to halt disease progression, as neurosyphilis arises from untreated or inadequately managed infection. is a nationally notifiable condition , requiring healthcare providers to report confirmed cases to local health departments, which aggregate data for the Centers for Disease Control and Prevention (CDC) to monitor trends and guide responses; this system facilitated tracking a 80% increase in primary and secondary syphilis cases from 2018 to 2022. Globally, the (WHO) coordinates syphilis surveillance through integrated STI programs, emphasizing data reporting from antenatal clinics to curb congenital transmission, a pathway to pediatric neurosyphilis. Routine screening forms the cornerstone of prevention, with CDC guidelines recommending syphilis serologic testing for high-risk groups including men who have sex with men, individuals with , and those in correctional facilities, alongside annual screening for sexually active persons in these categories. For pregnant individuals, universal screening at the initial prenatal visit is mandated, followed by third-trimester retesting and at delivery for those with risk factors such as prior or multiple partners, reducing rates by enabling prompt penicillin treatment. In 2023, enhanced CDC laboratory recommendations promoted the use of treponemal-specific tests like TP-PA for confirmatory diagnosis to improve accuracy in low-prevalence settings and support public health case management. Contact tracing and partner management are critical to breaking chains, with health departments conducting investigations to identify and presumptively treat exposed partners using expedited partner therapy where permitted, as outlined in CDC protocols. Public education campaigns promote use and risk reduction, with WHO estimating that consistent application prevents up to 80% of transmissions in discordant partnerships. In outbreak settings, such as the review of U.S. resurgence, combined interventions of case finding, rapid treatment, and community outreach have demonstrated efficacy in reducing incidence by 20-50% in targeted populations. Integration with services, including dual screening, addresses co-infection risks that elevate neurosyphilis likelihood.

Historical Context

Early Descriptions and Recognition

General paresis of the insane, a form of parenchymal , was first systematically described in by Antoine Laurent Jessé Bayle in his doctoral thesis, based on autopsies of asylum patients revealing chronic and progressive with . Bayle's work distinguished it as a distinct neurological entity, though its syphilitic etiology remained unestablished initially. Tabes dorsalis, another late neurosyphilitic manifestation involving dorsal column degeneration, was characterized in 1851 by German neurologist Moritz Heinrich Romberg, who detailed , lancinating pains, and proprioceptive loss, introducing the Romberg sign for testing postural instability in the dark. These descriptions highlighted pathology without immediate recognition of infectious cause. The etiological link to emerged in 1857 when surgeons Friedrich von Esmarch and Peter Willers Jessen reported cases attributing general paresis to prior syphilitic infection, observing high syphilis prevalence among affected individuals. This hypothesis gained traction through pathological correlations by figures like Jean Alfred Fournier and Wilhelm Erb, solidifying tertiary as the cause by the late . Additional diagnostic features, such as the —bilateral miotic pupils failing to react to light but preserving —were identified in 1869 by Scottish ophthalmologist Douglas Argyll Robertson in patients, further delineating neurosyphilitic pupillary involvement. These early clinical and pathological insights preceded microbiological confirmation of in 1905, marking progressive recognition of syphilis's neurotropism.

Pre-Antibiotic Era Treatments

Prior to the advent of antibiotics in the mid-20th century, treatments for neurosyphilis primarily involved compounds and experimental biological interventions, which offered limited efficacy against the invasion by while frequently inducing severe adverse effects. Mercury, employed since the 16th century as the cornerstone of antisyphilitic , was administered through cutaneous inunctions, oral ingestion, or vapor ; however, its poor penetration into rendered it largely ineffective for neurosyphilis, with chronic exposure leading to , , and fatal in up to 20% of cases. Arsphenamine (Salvarsan), the first organic arsenical synthesized by and introduced in 1910, marked a chemotherapeutic milestone by spirocheticidal action on early lesions, achieving serological cure rates exceeding 70% in primary stages; yet, its limited blood-brain barrier traversal confined benefits in neurosyphilis to transient stabilization rather than reversal, compounded by risks of and arsenical encephalopathy.30221-9/fulltext) salts, emerging in the 1920s as adjuncts, provided slower-acting alternatives with intramuscular administration but similarly inadequate cerebrospinal efficacy and cumulative toxicity, including hepatic failure. For refractory forms like (GPI), a late neurosyphilitic manifestation characterized by and , pioneered in 1917 by deliberately infecting patients with tertian (Plasmodium vivax) to provoke hyperpyrexia exceeding 40°C, postulating that sustained fevers (8-12 paroxysms) thermally eradicated heat-labile treponemes. This intervention, refined through controlled bites or blood transfusions, yielded clinical remissions in 27-42% of cases per contemporaneous series, averting institutionalization for many, though malaria-related mortality reached 10-15% and required termination to avert dissemination. 's method earned the in Physiology or Medicine and became the global standard for GPI until penicillin's supremacy, often augmented by tryparsamide—an arsenical variant introduced in 1919 with superior CSF penetration, achieving 20-30% seroreversion when combined with malariotherapy but at the cost of in 5-10% of recipients. These modalities underscored the era's causal emphasis on treponemal vulnerability to and thermal disruption, yet their empirical success was tempered by high iatrogenic burdens and incomplete eradication, with studies revealing persistent spirochetes in 50-70% of treated brains.

Antibiotic Revolution and Modern Insights

The by in 1928, followed by its mass production during , marked a pivotal shift in syphilis management, with initial clinical trials demonstrating its efficacy against Treponema pallidum by 1943. Early applications targeted neurosyphilis specifically, as intramuscular and intravenous regimens achieved treponemicidal concentrations in (CSF), eradicating infection in most cases without the toxicity of prior methods like malarial fever therapy or arsenicals. By halting bacterial replication, penicillin prevented progression in early and arrested neurological deterioration in established neurosyphilis, though it could not reverse preexisting structural damage such as or general paresis. Widespread penicillin use post-1945 led to a sharp decline in neurosyphilis incidence; by the early , reported cases had plummeted due to routine screening and treatment of primary and secondary , rendering neurosyphilis rare in developed regions. This antibiotic revolution supplanted ineffective pre-penicillin interventions, which had failure rates exceeding 50% and high mortality, with penicillin achieving serological cure rates over 90% in early stages and symptomatic improvement in 70-80% of late neurosyphilis patients. studies confirmed reduced syphilitic CNS lesions, validating penicillin's causal interruption of treponemal and . Contemporary guidelines affirm penicillin G as the definitive therapy for neurosyphilis, administered as aqueous crystalline penicillin G at 18-24 million units daily via intravenous infusion divided into 3-4 doses for 10-14 days, ensuring CSF penetration to kill persistent spirochetes. For penicillin-allergic patients, desensitization is recommended over alternatives like or , as T. pallidum exhibits no verified to beta-lactams, preserving penicillin's efficacy across strains isolated since the . Post-treatment monitoring involves repeat CSF examination at 6-12 months, with persistent pleocytosis or VDRL reactivity indicating in up to 10% of HIV-co-infected cases, where immune dysregulation may sustain low-level . Recent insights highlight a resurgence in neurosyphilis amid rising notifications—up 80% globally from 2010-2020—driven by behavioral factors rather than failure, with disproportionate cases in men who have with men and HIV-positive individuals exhibiting atypical presentations like acute . Empirical data underscore that early penicillin intervention arrests progression in 85-95% of symptomatic cases, but late correlates with irreversible sequelae, emphasizing causal links between untreated primary duration and CNS invasion probability exceeding 25% in untreated cohorts. Ongoing research explores adjunctive therapies, yet penicillin's bactericidal mechanism via cell wall inhibition remains unassailed, with no molecular evidence of resistance in clinical isolates.